Needham raised the firm’s price target on Neurocrine (NBIX) to $184 from $170 and keeps a Buy rating on the shares. The company reported a strong Q3, with EPS topping consensus thanks to better-than-expected product performance, the analyst tells investors in a research note. The management is again expanding its sales force by about 30% to continue driving Ingrezza volume growth ahead of IRA- related pricing pressure for Austedo starting 2027 and to broaden endocrinologist reach for Crenessity, the firm added, noting that Neurocrine remains well positioned to drive shareholder value with two scaled commercial assets and a deep, advancing pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine falls after DOJ sends Ingrezza investigative demand
- Neurocrine pullback despite ‘big quarter’ a buying opportunity, says RBC Capital
- Neurocrine price target raised to $183 from $174 at Stifel
- Neurocrine price target raised to $160 from $156 at RBC Capital
- Neurocrine price target raised to $146 from $145 at Mizuho